Trial

Read news on Trial with our app.

Read more in the app

RAS(ON) inhibitor doubles median overall survival in results of phase 3 trial for patients with metastatic pancreatic cancer - EurekAlert!

Cancer jab can eradicate entire tumours in patients, trial shows

Trial of next-gen weight-loss drug retatrutide brings it one step closer to FDA approval

Trial shows rapid weight loss is much more effective than gradual weight loss in achieving and sustaining clinically meaningful weight loss - EurekAlert!

First-in-human trial demonstrates promise of implantable cytokine factories for ovarian cancer - EurekAlert!

Trial now enrolling seeks to answer key question: Does adding chemotherapy to hormone therapy improve survival for metastatic prostate cancer? - EurekAlert!

Artemis 2's heat shield seems to have aced its trial by fire

First-in-human trial primes immune system to accept donor livers - EurekAlert!

Kiora’s phase 1 ABACUS study of KIO-301 in retinitis pigmentosa published in Nature Medicine; phase 2 trial underway - EurekAlert!

Novel, fast-acting therapy benefits patients with platelet disorder in phase 2 trial - EurekAlert!

Trial assesses safety and effectiveness of two new TB vaccines - EurekAlert!

Early results from a trial of active surveillance for low-risk DCIS are ‘reassuring’ - EurekAlert!

Trial for EBV (Epstein-Barr Virus) vaccine starts

From trial-and-error to intelligent design: Machine Learning boosts a breakthrough in the performance of BaTiO3-based High-Entropy energy-storage ceramics - EurekAlert!

Can DNA testing tell identical twins on trial apart?

Romiplostim prevents serious side effect of chemotherapy in phase 3 trial - EurekAlert!

Lipid nanoparticles: from trial-and-error to mechanism-based design

Ocean geoengineering trial finds no evidence of harm to marine life

The Lancet: New weight loss pill leads to greater blood sugar control and weight loss for people with diabetes than current oral GLP-1, phase 3 trial finds - EurekAlert!

Head-to-head trial shows Eli Lilly’s oral GLP-1 orforglipron outperforms oral semaglutide